|Closed||Lymphoproliferative Disease||Phase II||
The study is being conducted to demonstrate that CNTO 328 in combination with best supportive care is superior to best supportive care in terms of durable tumor and symptomatic response (reduction in tumor size and the symptoms for at least 18 weeks) and has an acceptable benefit risk profile in among patients with multicentric Castleman's disease.
|Ages Eligible for Study:||18 Years and older|
|Genders Eligible for Study:||Both|
|Accepts Healthy Volunteers:||No|
- Measureable and symptomatic Multicentric Castleman's Disease
- Adequate organ function as assessed by Laboratory values evaluated by the investigator to determine eligibility prior to treatment
- ECOG Performance Status of 0, 1, or 2
- Corticosteroids dose that does not exceed 1 mg/kg/day of prednisone, and has remained stable or decreased over the 4 weeks before treatment
- HIV or HHV-8 positive
- Skin lesions as sole measurable manifestation of MCD
- Prior exposure to IL-6 or IL-6 receptor targeted therapies
- Previous lymphoma
- Certain Malignancies, from which the patient has been disease-free for = 3 years
- Concurrent medical condition or disease that may interfere with study participation
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.